☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bms
BMS Reports Topline P-III (ARISE) Trial Data of Cobenfy as an Adjunctive Therapy for Schizophrenia
April 23, 2025
The US FDA Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma (HCC)
April 14, 2025
BMS Reports the US FDA’s Approval of Opdivo + Yervoy as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)
April 9, 2025
BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC
March 31, 2025
BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma
March 17, 2025
The EC Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma
March 10, 2025
Load more...
Back to Home
Modal title
×
Modal body text goes here.